RxDoctor Payments Data

Michelle Pittard

Family · Indianapolis, INNPI 1497421531

Payments from drug & device makers

$396in general payments, 2019–2025

Across 15 payments — averaging $26.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$166
  • Pfizer$82
  • Novo Nordisk$54
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$36
  • Phathom Pharmaceuticals, Inc.$17
  • Sanofi Pasteur Inc.$14
  • plus $26 from 2 others

What the payments were for

  • Food & beverage$396100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$396 in reported general payments places this provider in the 50th percentile of 4,392 family providers in Indiana.

See all family providers in Indiana

Medicare billing

Part B allowed, 2024
$15,123
Medicare patients
138
Services billed
264

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide26$31,812
Nurtec OdtRimegepant Sulfate11$18,225
MounjaroTirzepatide13$13,293
Albuterol Sulfate HfaAlbuterol Sulfate22$714
Metoprolol Succinate27$436
Gabapentin17$338
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav37$287
Fluticasone Propionate27$245
Amlodipine Besylate53$236
Omeprazole12$206
Atorvastatin Calcium25$196
Levothyroxine Sodium18$120
Diclofenac Sodium14$108
Doxycycline Hyclate15$108
Famotidine12$106

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$54$31,81226 claims
PfizerNurtec Odt$82$18,22511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 4,392 family providers in Indiana.

Other family in Indianapolis

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →